Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05712707 · ClinicalTrials.gov registry record · Phase 1
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
A Phase 1 study of Opioid Use Disorder and Opioid Withdrawal, sponsored by New York State Psychiatric Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 4
- Study locations
NCT05712707 is a Phase 1 study of Opioid Use Disorder and Opioid Withdrawal that is active but no longer recruiting, run by New York State Psychiatric Institute. The registered enrollment target is 160 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05712707, a Phase 1 study of Opioid Use Disorder and Opioid Withdrawal, is active but no longer recruiting, sponsored by New York State Psychiatric Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 4
- Study locations
Study Summary
A major challenge to seeking treatment for opioid use disorder (OUD) is the withdrawal symptoms associated with cessation of opioid use. The signs and symptoms of opioid withdrawal include irritability, anxiety, muscular and abdominal pains, chills, nausea, diarrhea, yawning, runny eyes and nose, sweating, sneezing, weakness, and insomnia. The current gold standard of treatment involves a gradual reduction of the opioid drug dosage (tapering). However, as all opioids have potential for abuse and require careful dosing due to side effects (e.g., respiratory depression), a non-opioid medication to facilitate withdrawal severity would be of great value. Commonly used non-opioid medications like lofexidine have concerning side effects including sedation and low blood pressure. BioXcel Therapeutics has developed BXCL501 (dexmedetomidine: sublingual film) to reduce symptoms associated with opioid withdrawal. Dexmedetomidine is currently used as an intravenous anesthetic for its anxiety-reducing, sedative, and analgesic properties. The current study will seek to compare the safety and efficacy of BXCL501 relative to lofexidine and placebo in subjects with OUD who are physically dependent on opioids. Throughout a 7-day inpatient withdrawal period (using a methadone taper) opioid-dependent participants will receive sublingual BXCL501, placebo, or lofexidine. In comparison to lofexidine, dexmedetomidine is expected to have a superior safety profile with limited adverse effects on blood pressure and heart rhythm. Three sites will participate in this study: NYSPI, Clinilabs, Inc., and Yale University. The NYSPI site is currently paused and has been paused since an institutional pause on human subjects research began in June 2023. The U.S. Department of Health and Human Services (HHS) Office of Human Research Protections (OHRP) issued an FWA restriction on NYSPI research that also included a pause of human subjects research as of June 23, 2023.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BXCL501 (180 micrograms)
- DRUG BXCL501 (240 micrograms)
- OTHER Lofexidine (Positive Control)
Study Locations (4)
New Jersey
- Clinilabs - Eatontown
- CenExel HRI - Marlton
Connecticut
- Yale University - New Haven
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05712707
The ClinicalTrials.gov registry entry for NCT05712707 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (97% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05712707 reports 4 study locations spanning 3 distinct geographic areas - top geographies include New Jersey, Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT05712707 about?
NCT05712707 is a clinical study titled "Sublingual Dexmedetomidine for Treating Opioid Withdrawal". A major challenge to seeking treatment for opioid use disorder (OUD) is the withdrawal symptoms associated with cessation of opioid use. The signs and symptoms of opioid withdrawal include irritability, anxiety, muscular and abdominal pains, chills, nausea, diarrhea, yawning, runny eyes and nose, sw...
What is the current status of trial NCT05712707?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2023-02-28. Estimated completion is 2026-08-31.
What conditions does trial NCT05712707 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Opioid Withdrawal.
What interventions are being tested in trial NCT05712707?
The interventions under investigation include: Placebo (OTHER), BXCL501 (180 micrograms) (DRUG), BXCL501 (240 micrograms) (DRUG), Lofexidine (Positive Control) (OTHER).
Who is sponsoring clinical trial NCT05712707?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05712707 being conducted?
This trial has 4 study locations across Connecticut, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
RECRUITING · Phase 1
-
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
RECRUITING · Phase 1
-
Cannabis and Opioid Use Disorder
RECRUITING · Phase 1
-
Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine
RECRUITING · Phase 1
-
A Bundled Intervention
RECRUITING · Phase 1
-
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.